Study on a 10-year protective effects of vaccination against hemorrhagic fever with renal syndrome.
- Author:
Zhen-Yu GONG
1
;
Jing-Qing WENG
;
Jin-Bao LEI
;
Chun-Fu FANG
;
En-Fu CHEN
;
Zhen WANG
;
Zhong-Bing CHEN
;
Wei WANG
;
Fan HE
;
Bi-Yao LIU
;
Jun-Fen LIN
;
Gang-Qiang DING
Author Information
- Publication Type:Journal Article
- MeSH: Adolescent; Adult; Animals; Female; Hemorrhagic Fever with Renal Syndrome; epidemiology; immunology; prevention & control; Humans; Immunization, Secondary; methods; Male; Middle Aged; Rats; Vaccination; methods; Viral Vaccines; administration & dosage; therapeutic use; Young Adult
- From: Chinese Journal of Epidemiology 2007;28(12):1190-1193
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo evaluate the epidemiological and serological efficacy after 10 years of vaccination against hemorrhagic fever with renal syndrome (HFRS) vaccines in Zhejiang province.
METHODSOne county was randomly chosen as the research unit with all the healthy people between 16 and 60 years old were equally divided into study and control groups. The study group was vaccinated. Immunofluorescent antibody assay was used to test specific IgG antibody and Mcro-CPE method was used to test the titer of neutralizing antibody.
RESULTSTwo weeks after the full-course immunization, the seroconversion rate became 100% (67/67, with 95% CI as 96.3%-100%) by immunofluorescent antibody test (IgG) and 44.4% (8/18 with 95% CI as 22.0%-69.0%) by neutralization test with GMT titers as 72.1 and 4.6 respectively. Booster immunization was provided one year later. Time span as two weeks prior to, one year, one and half years, two years, three years and five years after booster immunization, the rates of seroconversion on immunofluorescent antibody using IFAT method, were 28.6%, 83.3%, 75.0%, 53.1%, 22.6%, 10.0% and 55.0% respectively, and rates of seroconversion of neutralizing antibody by Mcro-CPE method were 14.8%, 55.6%, 35.0%, 31.3%, 26.0%, 10.0% and 50.0% respectively. Nine years after the reinforcement, the rates of seroconversion of immunofluorescent antibody by IFAT method was only 7.1%. The vaccinated group had no patient seen but the control group appeared 34 patients including 3 deaths. According to the ten-year observation, the vaccine seemed effective with the protection rate in population reached 100%.
CONCLUSIONHFRS vaccine was effective on epidemiological, social and economical efficacy.